Trials / Recruiting
RecruitingNCT06706570
PIK3CA Mutational Status Assessment
PIK3CA Mutational Status Assessment: Towards a "Tailored" Diagnostic Approach
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- European Institute of Oncology · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.
Detailed description
Evaluate the effectiveness and concordance of molecular methods in identifying mutations affecting the PIK3CA gene both on paraffin tissue sections of the tumor and on liquid biopsy of patients with breast cancer treated at the IEO. The molecular test on the liquid biopsy of same patient could bring an important benefit considering that the withdrawal of this biomaterial turns out to be less invasive than a biopsy performed on an organ
Conditions
Timeline
- Start date
- 2024-11-06
- Primary completion
- 2026-12-31
- Completion
- 2030-12-31
- First posted
- 2024-11-26
- Last updated
- 2026-03-24
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06706570. Inclusion in this directory is not an endorsement.